MIT-Backed Project Develops Wearable Patch for Early Heart Disease and Sepsis Detection

An interdisciplinary team at MIT has secured up to $38 million in funding from the U.S. Advanced Research Projects Agency for Health (ARPA-H) to develop PYTHIA, a four-year project focused on a wearable biosensor patch for early disease detection. The device targets heart failure and sepsis, conditions responsible for high mortality rates in the U.S., by tracking relevant biomarkers in real time.

PYTHIA is designed as a chip-based patch that obtains clinical-grade data by analyzing biomarkers in interstitial fluid beneath the skin. It detects molecules present at extremely low concentrations through a chemical reaction that binds biomarker molecules with specific chemicals, enhancing their detectability. This method aims to provide continuous, minimally invasive monitoring.

The patch operates using the patient’s body heat as its power source, ensuring low energy consumption and prolonged wearability without frequent recharging. On-chip artificial intelligence models process the voluminous data gathered, converting raw biomarker signals into actionable insights for clinicians. This approach facilitates near-continuous health assessment, akin to performing blood tests every 15 minutes, but automatically and noninvasively.

MIT’s engineering and chemistry experts—from electrical engineering to chemical engineering faculties—collaborate closely with clinical and industry partners to ensure the technology addresses real-world challenges. Their combined expertise supports translating laboratory innovation into a device viable for clinical use and eventual commercial manufacturing.

While promising, the project faces challenges including validating sensor accuracy in diverse patient populations and navigating regulatory pathways. Preclinical and clinical trials are planned to evaluate performance and safety before commercial scaling. The device's capability to influence treatment decisions remains to be demonstrated in clinical settings.

PYTHIA grew from MIT’s Program for Health Sciences and Semiconductors, reflecting a broader effort to leverage semiconductor and nanotechnology advances for health applications. By integrating bioelectronic sensing and AI-driven data interpretation, the project exemplifies the evolving landscape of personalized health care enabled by continuous monitoring technologies.